A compound extract of Terminalia chebula against drug-resistant Escherichia coli, its preparation method and application
The compound extract prepared by combining Terminalia chebula, Pulsatilla chinensis, and Glycyrrhiza uralensis solves the problem of poor targeting of traditional Chinese veterinary medicine compound extracts against drug-resistant Escherichia coli. It achieves effective elimination of drug-resistant Escherichia coli and remodeling of the intestinal microecology, repairs the mucosal barrier, and meets the technical requirements of modern animal husbandry.
Patent Information
- Application Number
- CN202611076186.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-20
- Publication Date
- 2026-11-17
AI Technical Summary
Existing traditional Chinese veterinary medicine compound formulations have poor targeting of drug-resistant Escherichia coli and lack multidimensional synergistic regulatory mechanisms, making it difficult to meet the technical requirements of modern animal husbandry for antibiotic alternatives.
A compound extract of Terminalia chebula was prepared by decocting and concentrating Terminalia chebula in a specific ratio of Terminalia chebula, Pulsatilla chinensis, and Glycyrrhiza uralensis. This extract is used to target and eliminate drug-resistant Escherichia coli, restore intestinal microecological homeostasis, and repair the mucosal barrier.
It significantly increases the activity of bacterial extracellular alkaline phosphatase, inhibits biofilm formation, reduces drug resistance, improves inflammatory response and oxidative stress, repairs intestinal mucosa, and reshapes the intestinal flora structure, thus achieving effective prevention and control of drug-resistant Escherichia coli.
Smart Images

Figure CN123101596A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of traditional Chinese veterinary medicine technology, specifically relating to a compound extract of Terminalia chebula var. chinensis resistant to drug-resistant Escherichia coli, its preparation method, and its application. Background Technology
[0002] Calf diarrhea primarily affects newborn calves and is characterized by high morbidity, rapid spread, and high mortality. Epidemiological surveys across multiple regions of China indicate that the morbidity rate of calf diarrhea is generally above 60%, with mortality rates reaching 10%–30%. Among bacterial pathogens, pathogenic *Escherichia coli* (ECC) is a significant contributor. Escherichia coli, E. coli Escherichia coli (E. coli) is the most common and serious pathogen. Numerous studies have confirmed that E. coli can colonize the intestines of calves through fimbriae adhesion factors and produce enterotoxins, causing severe secretory diarrhea. If not intervened in time, it can lead to secondary dehydration, acidosis, and septicemia. Calves that die from pathogenic E. coli infection alone can account for more than 50% of all beef cattle deaths, causing huge economic losses.
[0003] With the continuous expansion of beef cattle farming, the problem of drug resistance in Escherichia coli has become increasingly prominent. Existing literature reports that pathogenic Escherichia coli are generally resistant to commonly used clinical antibiotics such as β-lactams (e.g., amoxicillin), tetracyclines (e.g., tetracycline), and fluoroquinolones (e.g., enrofloxacin), and the detection rate of multidrug-resistant strains continues to rise. Under the macro-background of the national policy of continuously promoting "antibiotic reduction, antibiotic restriction, and antibiotic alternatives," the research and application of antibiotic alternatives has become an urgent need for the upgrading of the livestock industry. Traditional Chinese medicine, due to its wide availability, multiple effects including antibacterial, anti-inflammatory, intestinal flora regulation, and immune enhancement, as well as its diverse mechanisms of action, low likelihood of inducing drug resistance, and low toxicity and residues, has been recognized as an important source of antibiotic alternatives.
[0004] However, existing traditional Chinese veterinary medicine compound formulas for the prevention and treatment of Escherichia coli-induced diarrhea in calves still have significant shortcomings: on the one hand, most compound formulas are only designed for susceptible strains, and do not address those carrying other strains. sul1 , tetK The prevalent strains of drug-resistant genes lack targeted inhibition capabilities, and their clinical efficacy declines significantly with changes in the drug resistance spectrum. On the other hand, existing research on the mechanism of action of compound drugs mostly focuses on single antibacterial or anti-inflammatory effects, lacking a systematic explanation of the multidimensional synergistic regulatory mechanism of "gut microbiota-metabolic pathway-host barrier". This results in a lack of precise theoretical support for their application, making it difficult to meet the technical requirements of modern animal husbandry for antibiotic alternatives that are "clear in mechanism, clear in target, and stable in effect".
[0005] Among traditional Chinese herbs with astringent and antidiarrheal properties, Terminalia chebula (Hezi) is one such herb. Terminalia chebula Retz.As a commonly used traditional Mongolian and Chinese veterinary medicine, Terminalia chebula is rich in active ingredients such as tannins, flavonoids, and triterpenoids. Studies have confirmed that its extracts have significant in vitro antibacterial activity against Escherichia coli, and it also has unique advantages in astringing, consolidating, and repairing mucous membranes. However, current applications of Terminalia chebula are mostly limited to single-herb or simple combinations, and there are no reports of Terminalia chebula compound extracts designed based on a multidimensional synergistic mechanism of "microbiota-metabolism-barrier" targeting prevalent drug-resistant Escherichia coli strains.
[0006] Therefore, developing a compound extract of Terminalia chebula that can both target and eliminate drug-resistant Escherichia coli and repair the mucosal barrier by reshaping the intestinal microecological homeostasis has become one of the urgent problems to be solved by those skilled in the art. Summary of the Invention
[0007] In view of the shortcomings of the prior art, the present invention provides a compound extract of Terminalia chebula against drug-resistant Escherichia coli, its preparation method and application. The present invention uses Terminalia chebula, which has astringent, antidiarrheal, antibacterial and anti-inflammatory effects, as the core drug in a scientifically formulated prescription, overcoming the shortcomings of traditional compound prescriptions in terms of poor targeting of prevalent drug-resistant strains and unclear mechanisms.
[0008] To achieve the above objectives, the present invention provides the following technical solution: This invention provides a compound extract of Terminalia chebula that resists drug-resistant Escherichia coli. The raw materials of the compound extract are Terminalia chebula, Pulsatilla chinensis and Glycyrrhiza uralensis, and the mass ratio of Terminalia chebula, Pulsatilla chinensis and Glycyrrhiza uralensis is (1.5~2.5):(0.8~1.2):(0.8~1.2).
[0009] Preferably, the mass ratio of Terminalia chebula, Pulsatilla chinensis, and Glycyrrhiza uralensis is 2:1:1.
[0010] This invention also provides a method for preparing a compound extract of Terminalia chebula containing anti-drug-resistant Escherichia coli, comprising the following steps: (1) The Terminalia chebula, Pulsatilla chinensis and Glycyrrhiza uralensis were crushed separately and then mixed to obtain a mixture; (2) Mix the mixture with water, soak for 25-35 minutes, boil 1-3 times, filter and collect the filtrate, and combine the filtrates to obtain the mixed liquid; (3) The mixed liquid is concentrated to a concentration of 0.5~1.5g / mL to obtain the Terminalia chebula compound extract.
[0011] The present invention also provides the application of a compound extract of Terminalia chebula containing anti-drug-resistant Escherichia coli in the preparation of a drug for treating drug-resistant Escherichia coli infection.
[0012] Preferably, the drug-resistant Escherichia coli carries a sulfonamide resistance gene. sul1 and / or tetracycline resistance genes tetK .
[0013] The present invention also provides the application of a compound extract of Terminalia chebula against drug-resistant Escherichia coli in the preparation of a drug for treating drug-resistant Escherichia coli infection in combination with tetracycline antibiotics or sulfonamide antibiotics; the combination has a synergistic effect of inhibiting bacterial biofilm formation and / or reducing the expression of drug resistance genes.
[0014] Preferably, the tetracycline antibiotic is tetracycline, and the sulfonamide antibiotic is sulfadiazine.
[0015] This invention also provides the application of a compound extract of Terminalia chebula containing anti-drug-resistant Escherichia coli in the preparation of drugs for regulating intestinal flora.
[0016] Preferably, it increases the number of Firmicutes D in the gut. Firmicutes_D Lactobacillus family ( Lactobacillaceae ), Lactobacillus salivarius ( Ligilactobacillus ), genus *Terrigeron* Turicibacter ) or Bifidobacterium spp. Bifidobacterium The abundance of ) and / or inhibition of pathogenic Helicobacter spp. in the gut_C ( Helicobacter_C ) growth.
[0017] This invention also provides the application of a compound extract of Terminalia chebula containing anti-drug-resistant Escherichia coli in the preparation of drugs for relieving intestinal inflammation and repairing the intestinal mucosal barrier; the repair of the intestinal mucosal barrier is manifested by increasing the intestinal villus-cryptosome ratio and / or enhancing the activity of the intestinal glutathione metabolic pathway.
[0018] Compared with the prior art, the present invention has the following beneficial effects: (1) This invention isolated and identified a strain carrying a virus from the feces of diarrheal calves. sul1 , tetK This invention addresses a pathogenic *Escherichia coli* strain with drug-resistant genes, exhibiting multidrug resistance to several commonly used clinical antibiotics. The *Terminalia chebula* compound extract provided by this invention significantly increases the activity of extracellular alkaline phosphatase (AKP) in vitro, disrupting cell wall integrity; simultaneously, it effectively inhibits biofilm formation, reducing drug resistance and pathogenic potential, thus exerting its effects through both the clearance of drug-resistant bacteria and the attenuation of virulence.
[0019] (2) Synergistic relief of systemic inflammation and oxidative stress damage by multiple targets: The Terminalia chebula compound extract provided in this invention can simultaneously correct the imbalance of systemic inflammatory response and oxidative stress caused by Escherichia coli infection. In terms of inflammation regulation, the serum levels of pro-inflammatory factors TNF-α, IL-1β, and IL-6 are significantly reduced, while the level of anti-inflammatory factor IL-10 is significantly increased, thus restoring the pro-inflammatory / anti-inflammatory balance. In terms of antioxidant defense, the MDA content is significantly reduced, while the activities of T-AOC, SOD, and GSH-Px are significantly increased, indicating that the compound can effectively scavenge free radicals and enhance the body's antioxidant capacity, thereby reducing tissue damage caused by infection.
[0020] (3) Repairing the physical barrier of the intestinal mucosa and blocking the cascade amplification of inflammation: The Terminalia chebula compound extract provided by this invention can significantly improve the atrophy of small intestinal villi, structural disorder and crypt deepening caused by Escherichia coli infection, and restore the villus-crypt ratio (V / C) to near normal levels. By maintaining the integrity of the intestinal epithelial structure, this compound effectively reduces the translocation of endotoxins and bacterial products, blocking the vicious cycle of "dysbiosis-barrier damage-systemic inflammation" from the source, and achieving dual protection against local and systemic damage to the intestine.
[0021] (4) Targeted remodeling of gut microbiota homeostasis and activation of beneficial metabolic pathways: 16S rRNA high-throughput sequencing confirmed that the Terminalia chebula compound extract provided in this invention can specifically regulate the gut microbiota structure of infected mice: promoting Firmicutes D at the phylum level. Firmicutes_D Enrichment, significantly increasing the concentration of Lactobacillus salivarius at the genus level. Ligilactobacillus Lactobacillus ( ) Lactobacillus The abundance of probiotics such as ) and inhibited the opportunistic pathogenic bacteria Helicobacter spp. C ( Helicobacter_C Excessive proliferation. PICRUSt2 functional prediction showed that this microbiota remodeling was accompanied by enhanced activity of key pathways such as carbohydrate metabolism, amino acid metabolism, glutathione metabolism, and cell wall synthesis, further confirming its targeted repair ability of the gut microbiota at the functional level.
[0022] In summary, the Terminalia chebula compound extract provided by this invention can not only be used to prepare veterinary drugs against drug-resistant Escherichia coli infections, but also serve as a core active ingredient in feed additives, suitable for the prevention and treatment of drug-resistant bacterial diarrhea in livestock and poultry. It possesses a combination of antibacterial, anti-inflammatory, repairing, and bacterial-regulating effects, with a clear mechanism of action and good safety profile, providing a scientific basis and technical support for the application of traditional Chinese veterinary compound formulas in modern animal husbandry. Attached Figure Description
[0023] Figure 1 This is the result of MacConkey culture medium culture of bacteria in feces of diarrheal calves in an embodiment of the present invention; Figure 2 The results of bacterial Gram staining are shown in the embodiments of the present invention. Figure 3 The above are the 16S rRNA PCR agarose gel electrophoresis results of the isolated strains in this embodiment of the invention; Figure 4 This is the result of the drug-resistant inhibition zone of Escherichia coli in the embodiments of the present invention; Figure 5 This is the PCR detection result of Escherichia coli drug resistance gene in the embodiments of the present invention; Figure 6 This invention relates to the activity of extracellular AKP in Escherichia coli treated with traditional Chinese medicine in this embodiment of the invention. Figure 7 The results of the determination of Escherichia coli biofilm content by traditional Chinese medicine treatment in the embodiments of the present invention; Figure 8 The effects of Terminalia chebula compound extract on body weight (A), serum inflammatory factors (B), and antioxidant capacity (C) of mice infected with pathogenic Escherichia coli in this embodiment of the invention; Figure 9 This invention illustrates the effect of Terminalia chebula compound extract on intestinal slices and the depth of intestinal villi and crypts in mice infected with pathogenic Escherichia coli. Figure 10 The effect of Terminalia chebula compound extract on the diversity of intestinal flora in mice infected with pathogenic Escherichia coli in this embodiment of the invention; wherein, A: number of ASVs, B: α diversity, C: sparse curve and abundance level curve; Figure 11 The effect of Terminalia chebula compound extract on the intestinal flora structure of mice infected with pathogenic Escherichia coli in this embodiment of the invention; wherein, A: β diversity, B: UPGMA cluster analysis, C: Bray-curtis analysis; Figure 12 This is a bar chart showing the species distribution of gut bacteria at different taxonomic levels in an embodiment of the present invention; where A: phylum level, B: genus level. Figure 13 The effect of the compound extract on the intestinal marker flora of mice infected with pathogenic Escherichia coli in this embodiment of the invention; wherein, A: phylum level, B: genus level, C: LEfSe analysis; Figure 14 This invention relates to the effects of compound extracts on intestinal flora metabolism in mice infected with pathogenic Escherichia coli. Detailed Implementation
[0024] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0025] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.
[0026] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.
[0027] The technical solution of the present invention will be further described below with reference to the accompanying drawings and specific embodiments: Example 1 This embodiment describes a method for preparing a compound extract of Terminalia chebula containing anti-drug-resistant Escherichia coli. The specific steps are as follows: (1) Weigh out Terminalia chebula, Pulsatilla chinensis and Glycyrrhiza uralensis in a mass ratio of 2:1:1, pulverize them separately and pass them through a 40-mesh sieve, and mix them evenly to obtain a compound mixture; (2) Add the compound mixture to distilled water at a material-to-liquid ratio of 1:10 (g / mL) and soak at room temperature for 30 min; (3) After boiling over high heat, simmer over low heat twice, 40 minutes each time, and combine the filtrates; (4) Concentrate the filtrate under reduced pressure to a concentration of 1.0 g / mL (measured at 60℃) to obtain the Terminalia chebula compound extract.
[0028] Example 2 This example demonstrates the isolation, identification, phenotypic drug resistance, and genotypic verification of drug-resistant Escherichia coli.
[0029] 1. Sample collection and bacterial isolation and purification A total of 48 fresh fecal samples were collected from different cattle farms in Bijie City, Guizhou Province, including 32 samples of diarrhea and 16 samples of healthy feces. A portion of the fresh feces from each sample was immediately placed in a liquid nitrogen tank for preservation and sent to Wuhan Baiyi Huineng Biotechnology Co., Ltd. for 16S rRNA gene sequencing analysis.
[0030] Fecal samples were diluted 100-fold with sterile distilled water to form a suspension. 50 μL of the diluted suspension was inoculated onto MacConkey agar and streaked to isolate the bacterial strain. The culture was incubated at 37°C for 20–24 h. Single colonies that were light red, smooth, moist, and had well-defined edges were selected and streaked onto eosin methylene blue agar for purification, and incubated at 37°C for 20–24 h. Single colonies with a green metallic sheen and well-defined edges were then selected and purified again on eosin methylene blue agar. The purified suspected *E. coli* strain was inoculated into nutrient broth and incubated at 37°C for 24 h. 30% glycerol was then added, and the culture was stored at -20°C for later use.
[0031] 2. Identification of 16S rRNA gene The full-length 16S rRNA gene was amplified using universal primers 27F (5'-AGAGTTTGATCCTGGCTCAG-3') and 149R (5'-GGTTACCTTGTTACGACTT-3'). The PCR products were sequenced and compared with the GenBank database.
[0032] 3. Drug susceptibility test (KB disk diffusion method) Antimicrobial susceptibility testing was conducted using the KB disk diffusion method, in accordance with the standards of the Clinical and Laboratory Standards Institute (CLSI). A total of 20 commonly used clinical antibiotics from 12 classes were selected: β-lactams (amoxicillin, ampicillin, ceftriaxone, ceftiofur, ceftazidime, meropenem), aminoglycosides (gentamicin, streptomycin, amikacin), tetracyclines (tetracycline, doxycycline), quinolones (enrofloxacin, ciprofloxacin), chloramphenicol (florfenicol), sulfonamides (trimethoprim-sulfamethoxazole), polypeptides (polymyxin B), macrolides (erythromycin, azithromycin), lincosamides (lincomycin), and fosfomycin. Antimicrobial susceptibility results were classified as sensitive (S), intermediate (I), or resistant (R) according to CLSI standards. Multidrug resistance (MDR) was defined as resistance to three or more classes of antibiotics simultaneously.
[0033] 4. PCR detection of drug resistance genes For the identified E. coli, PCR amplification of drug resistance genes was performed, and 15 drug resistance genes were selected, including: aminoglycosides. aadA, aac(6')-1b, aac(3')-II and strA Genes, β-lactams blaCTX, blaTEM Genes, sulfonamides ul1, sul2 and sul3 Genes, tetracyclines tetA, tetC, tetK and tetM Genes, quinolones qnrS、qnrA Gene.
[0034] 5. Experimental Results (1) Bacterial isolation and identification: A total of 32 samples of diarrheal calves were collected in this study. Bacterial isolation and culture, biochemical identification, and 16S rRNA gene PCR identification were performed, resulting in the isolation of 20 pathogenic *Escherichia coli* strains, with an isolation rate of 62.5%. The isolates exhibited typical pinkish-red circular colonies with regular edges and smooth surfaces on MacConkey agar plates. Figure 1 Gram staining and microscopic examination revealed it to be a Gram-negative short bacillus with blunt, rounded ends, consistent with the typical morphological characteristics of Escherichia coli (e.g., Figure 2 16S rRNA gene sequencing was performed on 20 isolates, and all strains were correlated with those in GenBank. E. coli The homology of all reference strains was above 99%, confirming that all isolates were *Escherichia coli* (e.g., *Escherichia coli*). Figure 3 ).
[0035] (2) Determination of drug resistance phenotype (KB disc diffusion method): Two strains of *E. coli* isolated above were selected for susceptibility testing against 20 antimicrobial agents. The results of the inhibition zone susceptibility test showed that both strains exhibited multidrug resistance (MDR), showing resistance (R) to multiple classes of drugs including β-lactams, aminoglycosides, tetracyclines, and sulfonamides. The diameters of the inhibition zones against tetracycline (TET) and sulfadiazine (SDZ) were ≤10 mm and ≤12 mm, respectively, significantly lower than the susceptibility thresholds determined by CLSI (TET ≥ 15 mm; SDZ ≥ 16 mm), indicating that this *E. coli* is highly resistant to these two commonly used clinical antibiotics (e.g., sulfadiazine, sulfadiazine, sulfonamides, etc.). Figure 4 ).
[0036] (3) PCR verification of drug resistance genes: The above-mentioned drug-resistant Escherichia coli were subjected to PCR detection of 15 drug resistance genes, and the electrophoresis results are as follows: Figure 5 As shown: sul1 Gene (expected 425bp) and t etK All genes (expected 1159 bp) yielded specific amplification bands, with positions consistent with molecular weight markers, and no non-specific bands were observed.
[0037] Based on its resistance phenotypes to sulfadiazine and tetracycline, it can be inferred that this drug-resistant E. coli also carries sulfonamide resistance genes. sul1 and tetracycline resistance genes tetK Furthermore, their genotype and phenotype show consistent drug resistance characteristics (resistance to sulfonamides and tetracyclines).
[0038] Example 3 This embodiment is a screening of the in vitro antibacterial activity of candidate traditional Chinese medicines and a drug sensitivity test in combination with antibiotics.
[0039] 1. Preparation of Traditional Chinese Medicine Extracts To target the drug-resistant Escherichia coli screened in Example 2 above, 26 kinds of traditional Chinese medicinal materials, including Coptis chinensis, Schizonepeta tenuifolia, Polygonum cuspidatum, Portulaca oleracea, Akebia quinata, Pulsatilla chinensis, Viola yedoensis, Equisetum hyemale, Peucedanum praeruptorum, and Paeonia lactiflora, were selected for in vitro antibacterial tests. Extracts of the traditional Chinese medicines were prepared using water extraction and alcohol extraction methods, respectively. The water extract was decocted twice at a material-to-liquid ratio of 1:10 and concentrated to 1.0 g / mL; the alcohol extract was refluxed twice with 70% ethanol, concentrated, and then freeze-dried for later use. All extracts were sterilized by filtering through a 0.22 μm filter membrane before use.
[0040] 2. Determination of the minimum inhibitory concentration (MIC) of a single drug The MICs (micro-dissolved limits) of each herbal extract against the screened drug-resistant *E. coli* strains were determined using a 96-well plate micro-broth dilution method. Extracts were serially diluted twofold from their initial concentration, with 100 μL of the herbal extract and 100 μL of bacterial culture added to each well (final concentration 1 × 10⁻⁶). 5CFU / mL), and incubated at 37°C for 18 to 24 h. The minimum drug concentration at which no bacterial growth is observed visually (the broth is clear) is taken as the MIC value, and the medicinal material with the optimal antibacterial effect is selected for compatibility optimization of the compound prescription.
[0041] 3. Checkerboard dilution method combined drug susceptibility test The checkerboard dilution method is used for the combined drug susceptibility test to determine the minimum inhibitory concentration of the combined administration of the antibacterial traditional Chinese medicine extract and the antibiotic.
[0042] The traditional Chinese medicine extract is serially two-fold diluted from high concentration to low concentration along the transverse axis from left to right (8 gradients in total) and added to the 96-well plate; the antibiotic (initial concentration 128 μg / mL) is serially two-fold diluted from high concentration to low concentration along the longitudinal axis from top to bottom (8 gradients in total) and added to the 96-well plate.
[0043] A blank control is set, and Escherichia coli in the logarithmic phase (screened in Example 2) is inoculated, and the bacterial suspension concentration is adjusted to 1×10 5 CFU / mL, followed by incubation at 37°C for 18 to 24 h; the clarity of the broth in each well and the presence of sediment / bacterial film are first observed visually, then 10 μL is taken from the clear well with the minimum concentration and inoculated onto an LB solid plate for incubation, and the minimum drug concentration at which no colonies grow completely is taken as the combined MIC of this combination.
[0044] The drug susceptibility effect of the combination of the traditional Chinese medicine extract and the resistant antibiotic on this strain of drug-resistant Escherichia coli is evaluated by calculating the Fractional Inhibitory Concentration Index (FICI), and the calculation formula is as follows: Calculation formula: FICI=FIC(A)+FIC(B); In the formula: FIC(A) is the MIC of the traditional Chinese medicine extract when used in combination / the MIC of the traditional Chinese medicine extract when used alone; FIC(B) is the MIC of the combined antibiotic when used in combination / the MIC of the resistant antibiotic when used alone.
[0045] Evaluation criteria: FICI≤0.5: synergistic effect; 0.5<FICI≤0.75: partial synergistic effect; 0.75<FICI≤1: additive effect; 1<FICI≤4: indifferent effect; FICI>4: antagonistic effect.
[0046] 4. Experimental results (1) Screening of antibacterial activity of single drug: The MIC determination results of the above 26 Chinese herbal extracts against the screened drug-resistant Escherichia coli showed that the aqueous extract of Terminalia chebula had the best antibacterial effect, with a MIC value of 64 mg / mL. The aqueous and alcoholic extracts of the other 25 Chinese herbal extracts (including Coptis chinensis, Schizonepeta tenuifolia, Polygonum cuspidatum, Portulaca oleracea, Akebia trifoliata, Pulsatilla chinensis, Viola yedoensis, Equisetum hyemale, Peucedanum praeruptorum, Paeonia lactiflora, etc.) all had MIC values >128 mg / mL, and their antibacterial activity was significantly weaker than that of Terminalia chebula. Based on this, Terminalia chebula was determined to be the principal drug in the compound.
[0047] Although the MICs of Pulsatilla chinensis and Glycyrrhiza uralensis alone are >128 mg / mL, preliminary experiments showed that when combined with Terminalia chebula, they significantly enhanced the antibacterial efficacy of Terminalia chebula and reduced its effective dose. Through orthogonal optimization, the optimal mass ratio of Terminalia chebula:Pulsatilla chinensis:Glycyrrhiza uralensis = 2:1:1 was determined to be the best mass ratio.
[0048] (2) Results of drug sensitivity testing of Terminalia chebula aqueous extract and antibiotics: When used alone, the MIC of Terminalia chebula aqueous extract against the above strains was 64 mg / mL; the MIC of tetracycline against the strains was 128 μg / mL; and the MIC of sulfadiazine against the strains was 128 μg / mL.
[0049] When used in combination, the MIC concentration of Terminalia chebula aqueous extract was combined with the MIC concentration of tetracycline, resulting in a 64-fold decrease in the tetracycline MIC and a FICI of 0.078, exhibiting a synergistic effect. Similarly, when the MIC concentration of Terminalia chebula aqueous extract was combined with the MIC concentration of sulfadiazine, the MIC of sulfadiazine was decreased by 16-fold, with a FICI of 0.188, also showing a synergistic effect. This indicates that Terminalia chebula extract can effectively reverse the resistance of the aforementioned drug-resistant Escherichia coli to tetracyclines and sulfonamides.
[0050] Example 4 This example studies the antibacterial mechanism of Terminalia chebula compound extract against drug-resistant Escherichia coli; the Terminalia chebula compound extract prepared in Example 1 and the drug-resistant Escherichia coli screened in Example 2 were used.
[0051] 1. Alkaline phosphatase (AKP) activity assay The above-mentioned drug-resistant E. coli in the logarithmic growth phase were diluted to 1×10⁻⁶. 6 CFU / mL, divided into two groups: Treatment group (H): Add MIC concentration (64 mg / mL) of Terminalia chebula compound extract and incubate at 37°C for 2 h; Control group (HC): Add an equal volume of sterile LB liquid medium and incubate at 37°C for 2 hours.
[0052] The culture was centrifuged at 1500 rpm for 10 min, the precipitate was discarded, and the supernatant was collected. Extracellular AKP activity in the supernatant was measured using an alkaline phosphatase (AKP) activity assay kit (Solepro, BC6085), strictly following the manufacturer's instructions. Each sample was tested in triplicate, and results are expressed as mean ± standard deviation.
[0053] like Figure 6 As shown, the extracellular AKP concentration in the control group (HC) was (0.21±0.01), while the extracellular AKP concentration in the treatment group (HC) increased to (2.15±0.03), which was 10 times that of the control group. P <0.01); indicating that the MIC concentration of Terminalia chebula compound extract can significantly increase the extracellular AKP activity of Escherichia coli, which can destroy the bacterial cell wall, enhance cell wall permeability, and promote AKP release.
[0054] 2. Crystal violet staining of biological membranes The above-mentioned drug-resistant E. coli in the logarithmic growth phase were diluted to 1×10⁻⁶. 6 CFU / mL was inoculated into 12-well plates (1 mL per well) and incubated statically at 37°C for 24 h to allow mature biofilm formation. The original culture medium was discarded, and the plates were gently washed three times with PBS to remove airborne bacteria. The plates were then divided into two groups: Treatment group (H): Fresh LB medium containing MIC concentration (64 mg / mL) of Terminalia chebula compound extract was added and incubated overnight at 37°C; Control group (HM): Add an equal volume of sterile LB medium and incubate overnight at 37°C.
[0055] After incubation, the solution was discarded, washed three times with PBS, and dried in a fume hood. After fixation with methanol for 15 min, it was stained with 0.1% crystal violet, rinsed with distilled water until colorless, incubated with 95% ethanol for 15 min, and 200 μL of the destaining solution was transferred to a 96-well plate for OD measurement. 600 nm value.
[0056] like Figure 7 As shown, the control group (HM) biofilm OD 600 The nm value was 3.24 ± 0.05, while the treatment group (H)OD 600 The nm value was 1.71 ± 0.71; compared with the control group, the biofilm content in the treatment group decreased by 47.2% ( P <0.05). This indicates that the Terminalia chebula compound extract of the present invention not only has inhibitory activity against planktonic bacteria, but also has a significant scavenging / destructive effect on mature biofilms.
[0057] Example 5 This example illustrates the effects of Terminalia chebula compound extract on body weight, serum inflammatory factors, and antioxidant capacity in mice infected with Escherichia coli. The Terminalia chebula compound extract prepared in Example 1 and drug-resistant Escherichia coli screened in Example 2 were used.
[0058] 1. Experimental Design Healthy four-week-old male ICR mice were selected and purchased from Jiangsu Qinglongshan Experimental Animal Center. They were acclimatized for 2 days under an ambient temperature of 22±2℃ and a 12-hour light-dark cycle, with free access to food and water. A total of 30 four-week-old ICR mice were randomly divided into 3 groups (n=10 / group).
[0059] Blank control group (CE): intraperitoneal injection of normal saline + gavage administration of normal saline; Model group (ME): Intraperitoneal injection of Escherichia coli bacterial solution + gavage with physiological saline; Terminalia chebula compound extract treatment group (TE): intraperitoneal injection of Escherichia coli bacterial solution + oral administration of Terminalia chebula compound extract (100 mg / kg / d).
[0060] Log-phase Escherichia coli was resuspended in PBS and its OD was measured using a spectrophotometer. 600 The bacterial concentration was adjusted to 2×10⁻⁶. 8 CFU / mL. Mice in the ME and TE groups were intraperitoneally injected with 0.2 mL / mouse (i.e., 4 × 10⁻⁶ CFU / mL). 7 CFU / mouse); the CE group was injected intraperitoneally with an equal volume of sterile PBS. After modeling, the mice's mental state, activity level, and prickly hair were observed to confirm successful infection.
[0061] Two hours after model establishment, the first administration was started. The TE group was administered 100 mg / kg / day of Terminalia chebula compound (dissolved in physiological saline, 0.2 mL / mouse) by gavage. The CE and ME groups were administered the same volume of physiological saline by gavage once daily for 7 consecutive days. The weight of the mice was measured and recorded at the same time every day during this period.
[0062] 2. Sample collection and testing Twelve hours after the last administration, blood was collected from the eyes of mice, and serum was separated by centrifugation at 3000 rpm for 15 min and stored at -80℃ for later use. Mice were then euthanized by cervical dislocation, and rectal contents were aseptically collected, flash-frozen in liquid nitrogen, and sent for analysis. Serum inflammatory factors: TNF-α, IL-1β, IL-6, and IL-10 levels were detected by ELISA; serum antioxidant indicators: T-AOC, GSH-Px, SOD activities, and MDA levels were detected by colorimetric assay; gut microbiota: DNA was extracted from rectal contents and high-throughput sequencing of the 16S rRNA V3-V4 region was performed.
[0063] 3. Experimental Results (1) Weight change trend: like Figure 8 As shown in Figure A, there was no significant difference in baseline body weight among the groups of mice before infection (P>0.05). The body weight of the CE group showed a continuous upward trend throughout the experimental period. Compared with the CE group, the body weight of mice in the TE and ME groups decreased significantly after infection with Escherichia coli. Subsequently, the body weight of mice in the TE group recovered faster than that in the ME group. This indicates that the compound extract of Terminalia chebula of the present invention can effectively alleviate the weight loss caused by Escherichia coli infection.
[0064] (2) Serum inflammatory factor levels: like Figure 8 As shown in Figure B, compared with the CE group, the levels of interleukin-6 (IL-6), tumor necrosis factor (TNF-α), and interleukin-1β (IL-1β) in the serum of ME group mice were significantly increased, while the level of anti-inflammatory factor IL-10 was decreased, showing a typical acute inflammatory response. After treatment with the Terminalia chebula compound extract, the levels of TNF-α, IL-1β, and IL-6 in the TE group were lower than those in the ME group, while the level of IL-10 was higher than that in the ME group, suggesting that the Terminalia chebula compound extract of the present invention has a bidirectional regulatory effect on the balance of inflammatory factors.
[0065] (3) Serum antioxidant capacity like Figure 8 As shown in Figure C, the serum total antioxidant capacity (T-AOC), glutathione peroxidase (GSH-Px), and superoxide dismutase (SOD) levels in the ME group were significantly lower than those in the CE group, while the malondialdehyde (MDA) level was significantly higher, indicating that infection caused severe oxidative stress damage. Compared with the ME group, the serum T-AOC, GSH-Px, and SOD levels in mice treated with the Terminalia chebula compound extract were significantly increased, while the MDA level was significantly decreased, indicating that the Terminalia chebula compound extract of the present invention can significantly improve the oxidative stress state of infected mice.
[0066] Example 6 This embodiment evaluates the repair effect of the Terminalia chebula compound extract prepared in Example 1 on the small intestinal mucosal damage in mice infected with pathogenic Escherichia coli through histopathological observation. The experimental animals were mice in each group in Example 5 (blank control group CE, model group ME, and Terminalia chebula compound extract treatment group TE).
[0067] 1. Sample collection and slide preparation Twelve hours after the last drug administration, mice were sacrificed, and approximately 1 cm of mid-jejunum tissue was aseptically harvested. After gently rinsing the intestinal contents with PBS, the tissue was immediately fixed in 4% glutaraldehyde solution for 48 hours. The fixed tissue was then dehydrated with graded ethanol, embedded in paraffin, and cut into 5 μm thick serial sections for routine HE staining. Section preparation and staining were performed by Wuhan Pinofi Biotechnology Co., Ltd.
[0068] 2. Pathological observation and morphometric analysis The pathological changes in small intestinal tissue were observed and images were acquired using an Olympus GX41 optical microscope (Olympus Corporation, Japan). The following parameters were measured using Case Viewer image analysis software: Plum height: The vertical distance from the tip of the plum to the opening of the crypt; crypt depth: the vertical distance from the bottom of the crypt to the opening of the crypt; The villus-crypt ratio is the ratio of villus height to crypt depth, reflecting the state of small intestinal absorptive function.
[0069] 3. Experimental Results (1) Histopathological observation: like Figure 9 As shown, the morphology of the small intestine tissue in the three groups of mice showed significant differences. In the CE group: the intestinal mucosa structure was intact, the villi were neatly arranged, long and dense, the epithelial cells had good continuity, and no obvious inflammatory cell infiltration was observed. In the ME group: the intestinal mucosal barrier was severely damaged, the villi were significantly shortened, fused, or even detached, the crypts were dilated, and a large number of inflammatory cells were visible in the lamina propria, resulting in disordered tissue structure. In the TE group: after treatment with Terminalia chebula compound, the degree of small intestinal mucosal damage was significantly reduced compared to the ME group. Although the villi were still slightly shortened, they were basically neatly arranged, the continuity of the epithelial cells was partially restored, the inflammatory cell infiltration was significantly reduced, only focal defects were visible in the superficial mucosa, and the overall tissue structure was close to normal.
[0070] (2) The statistical data of the above small intestinal villus height, crypt depth and villus-crypt ratio are shown in Table 1.
[0071] Table 1 As shown in Table 1, compared with the CE group, the ME group exhibited significantly decreased villus height, significantly increased crypt depth, and significantly decreased villus-crypt ratio, confirming that E. coli infection led to a sharp reduction in the small intestinal absorptive area. After treatment with the Terminalia chebula compound extract of this invention, the villus height in the TE group significantly increased compared to the ME group, and the villus-crypt ratio was significantly higher than that in the ME group, indicating that the Terminalia chebula compound extract of this invention can effectively promote the repair of the small intestinal mucosal structure and restore intestinal absorptive function in infected mice.
[0072] Example 7 This embodiment evaluates the effects of the Terminalia chebula compound extract prepared in Example 1 on the intestinal flora structure and metabolic function of Escherichia coli-infected mice based on 16S rRNA gene high-throughput sequencing and PICRUSt2 functional prediction. The experimental animals were mice in the CE, ME, and TE groups (n=10 / group) from Example 5, and rectal contents were collected for analysis.
[0073] 1. Sequencing and Bioinformatics Analysis Total DNA was extracted using a fecal DNA kit. After integrity verification by 1.8% agarose gel electrophoresis, the V3-V4 region of the 16S rRNA gene was amplified using primers 338F-806R. Library construction was performed using the Hieff NGS® OnePot II kit, and sequencing was conducted on an Illumina NovaSeq 6000 platform. Raw data were denoising and denoising using DADA2 to generate ASVs, and species annotation (SILVA database) was performed using the QIIME2 platform. Venn diagrams were used for visualization to reveal common ASV characteristics among the three groups. α-diversity and β-diversity were calculated for each group using QIIME2 to comprehensively assess the richness, evenness, and structural differences of the microbial community. Linear discriminant analysis (LEfSe) and analysis of variance (ANOVA) were used to identify significantly different microbial communities among the groups. The PICRUSt2 algorithm was used to predict microbial community function, and the relative abundance of metabolic pathways in each group was compared using the KEGG and MetaCyc databases to reveal the functional characteristics and metabolic potential of the microbial community.
[0074] 2. Experimental Results (1) Effect of Terminalia chebula compound extract on the intestinal flora structure of mice infected with pathogenic Escherichia coli.
[0075] (i) Sequencing quality and alpha diversity: Sequencing quality control results showed that a total of 2,065,952 original sequences were obtained from the three groups of samples. After DADA2 denoising, splicing, and chimeric filtering, the effective sequence counts per sample in the CE, ME, and TE groups were 130,000-220,000, 170,000-260,000, and 170,000-250,000, respectively (as shown in Table 2), meeting the requirements for subsequent analysis. A total of 2,127 ASVs were identified in the three groups, including 1,319 in the CE group, 1,110 in the ME group, and 1,141 in the TE group; 524 ASVs were shared by all three groups, with 650 shared between the CE and ME groups and 648 shared between the CE and TE groups (as shown in Table 2). Figure 10 A).
[0076] Table 2 α-diversity analysis shows (as shown in Table 3, Figure 10 C), the observed species index was highly consistent with the Chao1 and ACE predicted species counts, and both the sparsity curve and abundance grade curve tended to flatten, confirming sufficient sequencing depth and data reliability. Intergroup comparisons showed that the ME group had the lowest species richness and low intragroup variation; the TE group had the highest average richness, with significantly better Shannon and Simpson diversity indices than the ME group, and a significantly improved Pielou evenness (e.g., ...). Figure 10(B) This suggests that the Terminalia chebula compound extract of the present invention can effectively restore the diversity and balance of the intestinal flora in infected mice.
[0077] Table 3 (ii) β-diversity and community structure differentiation: β-diversity analysis further reveals differences in community structure. Figure 11 The PCoA scatter plot showed a clear separation in the microbial composition of the three groups of samples (e.g., Figure 11 A); UPGMA clustering tree shows that the CE group samples form independent branches, and although the ME and TE groups have a small amount of overlap, they each cluster into their own branch (e.g. Figure 11 B); The Bray-Curtis distance matrix confirms that the differences between groups are significantly greater than the differences within groups (e.g., ...). Figure 11 C). The above results indicate that Escherichia coli infection leads to a significant shift in the intestinal flora structure, and intervention with the Terminalia chebula compound extract of the present invention can reshape the flora composition.
[0078] (2) Species composition analysis: Door horizontal (e.g.) Figure 12 A): All three groups were dominated by Bacteroidetes ( Bacteroidota ) and Firmicutes_A ( Firmicutes_A Corresponding to the traditional Firmicutes Core taxa) are dominant. The phylum Campylobacteria (ME) is the dominant phylum. Campylobacterota , 18.57%) and Firmicutes _D ( Firmicutes_D The percentage of cases in the TE group was abnormally high (12.55%); Firmicutes D was the dominant phylum in the TE group (43.76%), while Actinobacteria ( Actinobacteriota, 1.58% of the sample was specifically enriched, significantly higher than the CE / ME group.
[0079] Belongs to the level (e.g.) Figure 12 B): Group CE Muribaculaceae Related genus ( Paramuribaculum 12.99%, Duncaniella The majority (9.41%) were opportunistic pathogens in the ME group. Helicobacter_C (20.17%) and Ligilactobacillus (11.52%) significantly increased; probiotics in the TE group Ligilactobacillus (22.83%) Lactobacillus (12.50%) Bifidobacterium (1.65%) and Dubosiella (1.31%) significantly enriched, while Paramuribaculum and Duncaniella The low abundance indicates that the Terminalia chebula compound extract selectively promotes the colonization of beneficial bacteria such as Lactobacillus.
[0080] (3) Analysis of differentially expressed microbial biomarkers: Intergroup differential species screening: ANOVA results showed (e.g.) Figure 13 AB), compared with group CE, Firmicutes _D ( Firmicutes_D ) and its subgenus *Lactobacillus salivarius* ( Limosilactobacillus The levels of ( ) were significantly elevated in both the ME and TE groups (P<0.05); while those of *Ostreae bacillus* ( ) were significantly elevated. Odoribacter Both ) and UBA9715 were significantly reduced in the ME and TE groups (P<0.05), suggesting that the changes in these two bacterial groups were mainly driven by Escherichia coli infection, rather than by specific regulation by the Terminalia chebula compound extract.
[0081] LEfSe signature microbial enrichment characteristics: LEfSe analysis further revealed three unique groups of biomarkers (such as...) Figure 13 C). The taxonomic units enriched in group CE mainly belong to the phylum Bacteroidetes and related branches, including the family UBA11471 and its genera, and the family Rikenbacteria ( Rikenellaceae Christensenales ( Christensenellales ), Chitinophagales ( Chitinophagales ) and Spirulinaceae ( Saprospiraceae The OLB9 genus under the ME group reflects the homeostatic characteristics of Bacteroidetes as the core phylum in a healthy state. The ME group was significantly enriched in the genus *Faecidococcus*. Coprocola ) and anaerobic butyric acid-producing bacteria ( Anaerotignaceae Both belong to Firmicutes A, indicating that the infection led to abnormal proliferation of some taxa within this phylum. The hallmark bacteria of the TE group, however, are highly concentrated in Firmicutes D. Firmicutes_D ), encompassing the class Bacilli, order Lactobacillales, and family Lactobacillus. actobacillaceae ), Lactobacillus salivarius ( Ligilactobacillus ), Frischnella spp. Frisingicoccus ), Haloplasmasales ( Haloplasmatales_A ) and Terrigebrionaceae ( Turicibacteraceae ) and its genus *Terrigerella* ( Turicibacter ).
[0082] This result is consistent with the aforementioned species composition analysis, where Firmicutes D accounted for 43.76% of the TE group. Ligilactobacillus The abundance increased to 22.83%, indicating that the Terminalia chebula compound extract can reshape the gut microbiota through targeted enrichment of Firmicutes D probiotic groups.
[0083] (4) Differential microbiota metabolic analysis: PICRUSt2 functional prediction combined with KEGG and MetaCyc database analysis showed that the functional profiles of the microbial communities in the CE and TE groups were significantly differentiated (e.g., Figure 14).
[0084] Functional characteristics of the CE group: Significant enrichment of pathways including RNA polymerase, lysine degradation, phenylalanine metabolism, and N-glycan biosynthesis. These pathways mainly involve transcriptional regulation, amino acid catabolism, and glycosylation modification, reflecting the functional homeostasis of the gut microbiota in a healthy state, which is mainly maintained through basal metabolism and interaction with the host. Functional characteristics of the CE group: After intervention with the compound extract of Terminalia chebula, the TE group was enriched with more diverse functional pathways that were biased towards anabolic metabolism and energy supply. ① Energy and short-chain fatty acid metabolism: Propanoate metabolism and pyruvate metabolism were significantly upregulated, indicating enhanced acid production capacity. ② Protein synthesis and genetic information processing: Ribosome, Aminoacyl-tRNA biosynthesis, DNA replication, and base excision repair pathways were enriched, indicating improved bacterial proliferation activity and genome stability. ③ Antioxidant defense: Glutathione metabolism was significantly activated, consistent with the antioxidant phenotype of increased serum GSH-Px and decreased MDA. ④ Cell wall assembly: Peptidoglycan biosynthesis and D-glutamine / D-glutamate / D-alanine metabolic pathways were enriched, indicating the repair effect of the bacterial community on the intestinal mucosal barrier.
[0085] The above experimental results indicate that the Terminalia chebula compound extract of this invention exhibits a multi-target, multi-level synergistic therapeutic effect on mice infected with pathogenic Escherichia coli: ① At the systemic level, this compound can significantly reduce serum levels of pro-inflammatory factors TNF-α, IL-1β, and IL-6 and increase the level of anti-inflammatory factor IL-10, while simultaneously improving total antioxidant capacity (T-AOC) and glutathione peroxidase (GSH-Px) activity, and reducing malondialdehyde (MDA) content, effectively alleviating infection-induced systemic inflammatory response and oxidative stress damage; ② At the tissue level, it can significantly restore intestinal villus height, reduce crypt depth, and increase the villus-crypt ratio (V / C), demonstrating a clear protective and repairing effect on the intestinal mucosal barrier; ③ At the microecological level, species composition and differential marker analysis showed that after intervention, Lactobacillus ( Lactobacillaceae The abundance of probiotic groups such as Firmicutes D ( ) increased significantly, and the abundance of Firmicutes D ( ) increased significantly. Firmicutes_D ) and its subgenus *Lactobacillus salivarius* ( Ligilactobacillus ), genus *Terrigeron* Turicibacter ) became a marker microbial community with specific enrichment, and PICRUSt2 functional prediction revealed that this remodeling was accompanied by enhanced activity of key pathways such as carbohydrate metabolism, amino acid metabolism, glutathione metabolism and cell wall synthesis.
[0086] Furthermore, the targeted enrichment of Firmicutes D and the activation of the glutathione metabolic pathway are causally linked to the improvement of host antioxidant indicators and mucosal barrier repair at the level of microecological metabolism, suggesting that the Terminalia chebula compound exerts its therapeutic effect through the "microbiota-metabolism-host" axis. Although there are differences in the distribution of Proteobacteria and Campylobacteria among the groups, the significant enrichment of probiotics and the overall upregulation trend of beneficial metabolic pathways indicate that the compound has a generally beneficial regulatory effect on the intestinal microbiota.
[0087] In summary, the Terminalia chebula compound extract provided by this invention is effective for patients carrying... sul1 and / or tetK This extract exhibits significant inhibitory effects on drug-resistant pathogenic Escherichia coli, disrupting bacterial cell wall integrity and inhibiting biofilm formation. Simultaneously, it regulates the intestinal flora structure, increasing the abundance of beneficial bacteria such as Firmicutes D and Lactobacillus salivarius, while inhibiting the growth of pathogenic Helicobacter spp. C. Furthermore, it alleviates intestinal inflammation and repairs the mucosal barrier by enhancing glutathione metabolism pathway activity. The extract can also be used in combination with tetracycline or sulfonamide antibiotics to exert a synergistic anti-drug resistance effect. This invention combines targeted antibacterial activity, microecological remodeling, and mucosal repair, making it suitable for preparing drugs to treat drug-resistant Escherichia coli infections and regulate intestinal flora, providing a new solution for antibiotic alternatives in livestock and poultry bacterial diarrhea.
[0088] The foregoing has provided a detailed description of a compound extract of Terminalia chebula for combating drug-resistant Escherichia coli, its preparation method, and its applications. Specific examples have been used to illustrate the principles and implementation methods of this invention. The descriptions of these examples are merely for the purpose of helping to understand the method and core ideas of this invention. It should be noted that those skilled in the art can make various improvements and modifications to this invention without departing from its principles, and these improvements and modifications also fall within the scope of protection of the claims of this invention.
Claims
1. A compound extract of Terminalia chebula against drug-resistant Escherichia coli, characterized in that, The raw materials of the Terminalia chebula compound extract are Terminalia chebula, Pulsatilla chinensis and Glycyrrhiza uralensis, and the mass ratio of Terminalia chebula, Pulsatilla chinensis and Glycyrrhiza uralensis is (1.5~2.5):(0.8~1.2):(0.8~1.2).
2. The Terminalia chebula compound extract for resisting drug-resistant Escherichia coli according to claim 1, characterized in that, The mass ratio of Terminalia chebula, Pulsatilla chinensis, and Glycyrrhiza uralensis is 2:1:
1.
3. A method for preparing a compound extract of Terminalia chebula against drug-resistant Escherichia coli as described in claim 1 or 2, characterized in that, Includes the following steps: (1) The Terminalia chebula, Pulsatilla chinensis and Glycyrrhiza uralensis were crushed separately and then mixed to obtain a mixture; (2) Mix the mixture with water, soak for 25-35 minutes, boil 1-3 times, filter and collect the filtrate, and combine the filtrates to obtain the mixed liquid; (3) The mixed liquid is concentrated to a concentration of 0.5~1.5g / mL to obtain the Terminalia chebula compound extract.
4. The use of the Terminalia chebula compound extract for treating drug-resistant Escherichia coli as described in claim 1 in the preparation of a drug for treating drug-resistant Escherichia coli infection.
5. The application according to claim 4, characterized in that, The drug-resistant Escherichia coli carries a sulfonamide resistance gene. sul1 and / or tetracycline resistance genes tetK .
6. The use of the Terminalia chebula compound extract for anti-drug-resistant Escherichia coli as described in claim 1 in the preparation of an anti-drug-resistant Escherichia coli infection drug in combination with tetracycline antibiotics or sulfonamide antibiotics; wherein the combination has a synergistic effect of inhibiting bacterial biofilm formation and / or reducing the expression of drug resistance genes.
7. The application according to claim 6, characterized in that, The tetracycline antibiotic is tetracycline, and the sulfonamide antibiotic is sulfadiazine.
8. The use of the Terminalia chebula compound extract for resisting drug-resistant Escherichia coli as described in claim 1 in the preparation of drugs for regulating intestinal flora.
9. The application according to claim 8, characterized in that, Increase the number of Firmicutes D in the gut. Firmicutes_D Lactobacillus family ( Lactobacillaceae ), Lactobacillus salivarius ( Ligilactobacillus ), genus *Terrigeron* Turicibacter ) or Bifidobacterium spp. Bifidobacterium The abundance of ) and / or inhibition of pathogenic Helicobacter spp. in the gut_C ( Helicobacter_C ) growth.
10. The application of the Terminalia chebula compound extract for resisting drug-resistant Escherichia coli as described in claim 1 in the preparation of drugs for relieving intestinal inflammation and repairing the intestinal mucosal barrier; wherein the repair of the intestinal mucosal barrier is manifested by increasing the intestinal villus-cryptosome ratio and / or enhancing the activity of the intestinal glutathione metabolic pathway.
